Physician profile
Steven Rocker
NPI 1861513038
$9,598.55
in general payments reported to CMS, 2019-2025
44 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,046 · 2020: $2,295 · 2021: $1,171 · 2022: $152 · 2023: $1,057 · 2024: $1,265 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,935.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,809.39 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $957.30 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $950.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $748.93 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $738.51 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $687.01 | 2019-2025 | |
| Lilly USA, LLC | $593.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $369.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $331.37 | 2019-2021 | |
| Allergan, INC. | $290.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $255.92 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $206.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $193.80 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.79 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $170.19 | 2019-2024 | Eliquis, Camzyos |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.